resiquimod has been researched along with Anthrax in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ainslie, KM; Bachelder, EM; Bell, MG; Borteh, H; Elberson, MA; Fonseca, ME; Gallovic, M; Keane-Myers, A; Peine, KJ; Pesce, J; Prouty, AM; Schully, KL; Sharma, S | 1 |
| Cottam, HB; Guiney, DG; Sabet, M | 1 |
2 other study(ies) available for resiquimod and Anthrax
| Article | Year |
|---|---|
Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by bacillus anthracis.
Topics: Acetylation; Animals; Anthrax; Anthrax Vaccines; Antibody Formation; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; Dextrans; Drug Carriers; Imidazoles; Mice; Toll-Like Receptors; Vaccination; Vaccines, Subunit | 2013 |
Modulation of cytokine production and enhancement of cell viability by TLR7 and TLR9 ligands during anthrax infection of macrophages.
Topics: Aminoquinolines; Animals; Anthrax; Bacillus anthracis; Cell Survival; Cells, Cultured; Cytokines; Imidazoles; Ligands; Macrophages; Membrane Glycoproteins; Mice; Mice, Inbred A; Spores, Bacterial; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2006 |